Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia.

456Objectives: 225Ac-lintuzumab is a radioimmunoconjugate composed of 225Ac, which emits 4 α-particles, linked to a humanized anti-CD33 monoclonal antibody. An initial phase I trial showed that a single infusion of 225Ac-lintuzumab is safe at doses ≤ 111 kBq/kg and has activity in relapsed/refractory acute myeloid leukemia (AML). We conducted a multicenter, phase I dose-escalation trial to determine the maximum tolerated dose (MTD), toxicity, and biological activity of fractionated-dose 225Ac-lintuzumab in combination with low-dose cytarabine (LDAC).Methods: Patients 蠅 60 years with untreated AML not candidates for intensive chemotherapy were eligible. Patients received LDAC 20 mg twice daily for 10 days every 4-6 weeks for up to 12 cycles. During Cycle 1, 2 fractions of 225Ac-lintuzumab were given 1 week apart, beginning 4-7 days following completion of LDAC. To prevent radiation-induced nephrotoxicity, patients were given furosemide while receiving 225Ac-lintuzumab then spironolactone for 1 year afterward. Four dose levels of 225Ac-lintuzumab were studied using a 3+3 design.Results: Eighteen patients (median age, 77 years; range, 68-87) completed therapy. Twelve (67%) had prior myelodysplastic syndrome (MDS), for which 10 (83%) received therapy with hypomethylating agents (n=9) or allogeneic hematopoietic cell transplantation (n=1). Eleven patients (61%) had intermediate-risk and 7 (39%) had poor-risk AML. Median CD33 expression was 81% (range, 30-100%). 225Ac...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Radiopharmaceutical Therapy- Radioimmunotherapy and Radioembolization Source Type: research

Related Links:

Authors: Lee S, Cohen DJ Abstract INTRODUCTION: Esophageal cancer is a heterogeneous cancer comprised of differing cells of origin, molecular changes, and immune microenvironments. To date, most advances have been made in chemotherapy regimens where a one-size-fits-all approach is used. As a result, there remains a lack of tailored treatment options for such a heterogeneous cancer. This paper highlights the current standard of care treatment options as well as active areas of clinical research. Areas covered: The authors review the key trials that have led to current standard of care treatment including pivotal che...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Conclusion: Early and frequent PT may be important for patients admitted to the intensive care unit while awaiting transplantation and can play an even greater role for the less than “ideal” transplant candidate. The PT interventions can be provided safely for this population in the hospital setting. A rehabilitation approach focused on maximizing a patient's functional capacity with strength and gait training activities may facilitate improved outcomes for lung transplant recipients deemed less than optimal candidates.
Source: The Journal of Acute Care Physical Therapy - Category: Physiotherapy Tags: Case Reports Source Type: research
CONCLUSIONS: ONJ is an important complication of BPs medication. The majority of affected patients develop this complication after dentoalveorar surgery, especially after dental extraction. Therefore, a good state of dental health is one of the most important directives when dealing with potential candidates for BPs therapy. PMID: 30534822 [PubMed - in process]
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research
Authors: Passouant O, Hentzien M, Viguier M, Vernet-Garnier V, Bani-Sadr F, Cousson J PMID: 30528272 [PubMed - as supplied by publisher]
Source: Medecine et Maladies Infectieuses - Category: Infectious Diseases Tags: Med Mal Infect Source Type: research
T-cell acute lymphoblastic leukemia (T-ALL) is less common than B-cell acute lymphoblastic leukemia (B-ALL) in pediatric as well as adult malignancies, comprising 15% of ALL cases in children and 25% of cases in adults [1]. However, the relative adverse outcome of T-ALL warrants special attention, with many pathogenic gene mutations having been identified. Rapid identification of clone specific subgroups is of primary importance for stratifying responses to treatment, with the ultimate goal of improving cure rates.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Tags: Original Article Source Type: research
To evaluate outcomes after focal ablative therapy for renal cell carcinoma (RCC) in transplant allograft kidneys
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
Immune-checkpoint inhibitors may provide long-term survival benefits via a cured proportion, yet data are usually insufficient to prove this upon submission to health technology assessment bodies.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Authors: Kim JM PMID: 30531662 [PubMed - as supplied by publisher]
Source: Clinical and molecular hepatology - Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research
CONCLUSION: Racial disparities in HCC treatment exist despite emphasis to support equality in healthcare. African-American patients are less likely to undergo curative treatments for HCC. PMID: 30533185 [PubMed]
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Authors: Qu Z, Krauth C, Amelung VE, Kaltenborn A, Gwiasda J, Harries L, Beneke J, Schrem H, Liersch S Abstract As the gap between a shortage of organs and the immense demand for liver grafts persists, every available donor liver needs to be optimized for utility, urgency and equity. To overcome this challenge, decision modelling might allow us to gather evidence from previous studies as well as compare the costs and consequences of alternative options. For public health policy and clinical intervention assessment, it is a potentially powerful tool. The most commonly used types of decision analytical models include...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Atrial Fibrillation | Chemotherapy | Furosemide | Hematology | History of Medicine | Immunotherapy | Leukemia | Myelodysplastic Syndrome | Nuclear Medicine | Pneumonia | Spironolactone | Thrombocytopenia | Toxicology | Transplants